Safety of Infliximab Following Live Virus Vaccination in Kawasaki Disease Patients
No published data are available regarding infliximab use in Kawasaki disease patients with recent live virus vaccination. We investigated 38 acute Kawasaki disease patients who received infliximab within 90 days of receiving measles-mumps-rubella, varicella-zoster virus, or Rotavirus
vaccines. There were no adverse events or serious infections, which suggests that infliximab use in acute Kawasaki disease patients with recent live viral vaccinations is safe.
Keywords: Kawasaki disease; infection; infliximab; tumor necrosis factor alpha; viral vaccine
Document Type: Research Article
Publication date: 01 April 2017
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content